walvax biotechnology co-a
(300142:Shenzhen)
walvax biotechnology co-a (300142) Snapshot
|
Open
CNY41.30
|
Previous Close
CNY41.51
|
|
|
Day High
CNY41.79
|
Day Low
CNY40.56
|
|
|
52 Week High
08/21/12 - CNY48.00
|
52 Week Low
12/4/12 - CNY31.00
|
|
|
Market Cap
7.4B
|
Average Volume 10 Days
930.5K
|
|
|
EPS TTM
CNY1.29
|
Shares Outstanding
182.2M
|
|
|
EX-Date
--
|
P/E TM
31.6x
|
|
|
Dividend
CNY0.25
|
Dividend Yield
0.61%
|
Related News
walvax biotechnology co-a (300142) Related Businessweek News
No Related Businessweek News Foundwalvax biotechnology co-a (300142) Details
Walvax Biotechnology Co., Ltd., a biological pharmaceutical company, engages in the research and development, production and sale of bio-medicine products in China and internationally. It offers bio-medicine, such as vaccines and blood products. The company’s products include Haemophilus influenzae type b conjugate vaccine for infants from the age of 2 months to 5 years to induce immunization against infectious diseases, such as meningitis, pneumonia, septicemia, cellulitis, arthritis, and epiglottitis; and Group A, C Meningococcal Polysaccharide conjugate vaccine for infants from the age of 3 months to 5 years preventing diseases, such as cerebrospinal meningitis and septicemia. Walvax Biotechnology Co., Ltd. was founded in 2001 and is headquartered in Kunming, China.
walvax biotechnology co-a (300142) Key Developments
Walvax Biotechnology Co.,Ltd held its annual general meeting of 2012 on 10 May 2013. In the meeting, shareholders of the company approved tax included cash dividend of CNY 2.500 per ten share for the financial year 2012.
Walvax Biotechnology Co.,Ltd announced that they will report Q1, 2013 results on Apr 26, 2013
Walvax Biotechnology Co.,Ltd announced that they will report fiscal year 2012 results on Apr 18, 2013
| Recently Viewed | |||
| 300142:CH | CNY40.74 CNY | -0.77 |  |
| Company | Last | Change | |
| No competitor information is available for 300142. | |||
| View Industry Companies | |||
Industry Analysis
300142
Industry Average
| Valuation | 300142 | Industry Range |
| Price/Earnings | 32.4x |
|
| Price/Sales | 13.5x |
|
| Price/Book | 2.6x |
|
| Price/Cash Flow | 32.5x |
|
| TEV/Sales | 9.9x |
|
Post a JobJobs
- Orlando, FL | Consult SoftPosted: May 22
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
Sponsored Financial Commentaries
Sponsored Links
To contact WALVAX BIOTECHNOLOGY CO-A, please visit www.walvax.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
